No Prescription |
 |
 | ||
|
Vagifem Vaginal Generic 17 oestradiol |
|
| ||
No Prescription » Prescription Drugs 16 » Vagifem Vaginal Generic 17 oestradiol IndicationsVagifem is indicated for the treatment of atrophic vaginitis due to oestrogen deficiency.Dosage and AdministrationVagifem is administered deeply into the vagina using the applicator.Initial dose: 1 vaginal tablet a day for two weeksMaintenance dose: 1 vaginal tablet twice a week.Treatment may be started on any convenient day. If a dose is forgotten it should be taken as soon as the patient remembers. A double dose should be avoided.For initiation and continuation of treatment of postmenopausal symptoms the lowest effective dose for the shortest duration should be used (see Warnings and Precautions).Vagifem may be used in women with or without an intact uterus.During treatment especially during the first 2 weeks minimal absorption may be seen but as plasma oestradiol levels after the first 2 weeks usually do not exceed postmenopausal levels the addition of a progestagen is not recommended.AdministrationOpen the blister pack at the plunger end. Insert the applicator in the vagina until resistance is met (8-10 cm). Release the tablet by pressing the plunger. Withdraw the applicator and discard. Buy Vagifem Vaginal Generic 17 oestradiol and other Prescription Drugs 16 products online at Medstore. 3591
About Vagifem Vaginal Generic 17 oestradiol: Product Type: Prescription Drugs 16 Vagifem Vaginal ( Generic 17-oestradiol Estradiol ) Vagifem Vaginal (Generic 17-oestradiol Estradiol) Generic 17-oestradiol Estradiol 25mcg 15 Tablets Generic 17-oestradiol Estradiol Vagifem Vaginal
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
